

### **REMARKS**

Favorable reconsideration is respectfully requested in view of the foregoing amendments and following remarks.

Claim 40 has been amended to require that the glycerolipid contain specific fatty acid(s). Support for the amendment is found in the specification at page 10, lines 14-25, and in the Examples of the specification.

Claims 40-47 have been rejected under 35 USC 103 as being unpatentable over Hibino et al., Gilchrest et al., Giaccia et al., Nakai et al. and Nelson et al. This ground of rejection is respectfully traversed as applied to the claims after the foregoing amendments.

Hibino et al. disclose that a glycerolipid, diacylglycerol containing DHA, is useful for treating cancer. This reference only discloses a diacylglycerol containing docosahexaenoic acid.

Gilchrest et al. disclose that a glycerolipid, diacylglycerol, activates protein kinase C (PKC). However, this reference does not disclose any concrete diacylglycerol molecule.

Giaccia et al. disclose that PKC activators are useful in treating cancer. This reference only discloses 2-acetyl-1-oleylglycerol at column 2, lines 25-29.

Nakai et al. only disclose that apoptosis involves a process of cancer cell death in the treatment of cancer.

Nelson et al. only disclose a method for separating and purifying glycerolipid including using an acid treatment.

None of the cited references disclose or suggest a method for inducing apoptosis, by administering an apoptosis inducing agent which comprises an isolated glycerolipid which contains the specific fatty acid(s) defined in claim 40.

Accordingly, it is respectfully submitted that the claims as amended are patentably distinct and not obvious over the combined teachings of the cited references.

Favorable reconsideration and allowance is respectfully solicited.

Respectfully submitted,

Takeshi SAKAI et al.

By: Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
September 25, 2003